Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09MKQ
|
|||
| Former ID |
DCL000424
|
|||
| Drug Name |
AMG 317
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Discontinued in Phase 1 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 4 receptor alpha (IL4R) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| IL4-mediated signaling events | ||||
| WikiPathways | Inflammatory Response Pathway | |||
| IL-4 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017312) | |||
| REF 2 | Clinical pipeline report, company report or official report of Amgen (2009). | |||
| REF 3 | Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis. 2010 Jul;16(7):1209-18. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.